

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau

(43) International Publication Date  
27 January 2022 (27.01.2022)



(10) International Publication Number  
**WO 2022/020388 A1**

(51) International Patent Classification:

C12Q 1/00 (2006.01) G01N 30/00 (2006.01)  
C12Q 1/37 (2006.01) G01N 33/48 (2006.01)

(21) International Application Number:

PCT/US2021/042426

(22) International Filing Date:

20 July 2021 (20.07.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/054,525 21 July 2020 (21.07.2020) US

(71) Applicant: **AMUNIX PHARMACEUTICALS, INC.**  
[US/US]; 500 Ellis Street, Mountain View, CA 94043 (US).

(72) Inventors; and

(71) Applicants: **SCHELLENBERGER, Volker** [US/US];  
914 Moreno Avenue, Palo Alto, CA 94303 (US). **REN-  
NERFELDT, Deena** [US/US]; 525 Middlefield Rd., Apt.  
1082, Redwood City, CA 94063 (US). **HENKENSIE-  
FKEN, Angela** [US/US]; 1390 Saddle Rack Street, # 204,  
San Jose, CA 95126 (US). **TO, Milton** [US/US]; 14811  
Wake Ave, San Leandro, CA 94578 (US).

(74) Agent: **HELWIG, Bryan, G.**; McDonnell Boehnen Hul-  
bert & Berghoff LLP, 300 South Wacker Drive, Chicago,  
IL 60606 (US).

(81) Designated States (unless otherwise indicated, for every  
kind of national protection available): AE, AG, AL, AM,  
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,  
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,  
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,  
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,  
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,  
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,  
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,  
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,  
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every  
kind of regional protection available): ARIPO (BW, GH,  
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,  
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,  
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,  
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,  
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,  
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS AND METHODS RELATED TO ACTIVATABLE THERAPEUTIC AGENTS

(57) Abstract: Described herein are methods for assessing likelihood of response of subjects to activatable therapeutic agents and compositions, kits, and methods of preparing and using activatable therapeutic agents. Also described herein are methods for assessing likelihood of response of subjects to activatable therapeutic agents. In some cases, the activatable therapeutic agents of the compositions, kits, and methods disclosed herein can comprise a mammalian protein-derived sequence.

WO 2022/020388 A1